Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14323389 | 0.84 | KDM4E (0.40) | ALDH1A1MAPTKDM4EPKMTDP1 | |
| SCHEMBL1266021 | 0.81 | MMP12 (0.42) | ALDH1A1MAPTKDM4ETDP1MMP12 | |
| SCHEMBL11783635 | 0.79 | JAK2 (0.41) | TNNI3KMAPTKDM4EMMP12PRKCI | |
| SCHEMBL362000 | 0.78 | POLB (0.50) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| Potassium Ion SCHEMBL2918768 | 0.78 | PRKCI (0.42) | ALDH1A1MAPTKDM4EPKMTDP1 | |
| SCHEMBL27786197 | 0.78 | PRKCI (0.42) | ALDH1A1MAPTKDM4EPKMTDP1 | |
| SCHEMBL571363 | 0.78 | PRKCI (0.42) | ALDH1A1MAPTKDM4ETDP1HTT | |
| SCHEMBL4429284 | 0.78 | PRKCI (0.42) | ALDH1A1MAPTKDM4ETDP1HTT | |
| SCHEMBL31647242 | 0.77 | TAS2R14 (0.51) | TNNI3KHTTLMNASMN1; SMN2HTR6 | |
| SCHEMBL28975737 | 0.77 | HDAC6 (0.41) | ALDH1A1MAPTKDM4ETDP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| CN-1976706-B | FGFR3 inhibition and treatment of multiple myeloma | NOVARTIS VACCINES & DIAGNOSTIC | 2012-01-18 | — | — | CN | disclosed |
| CN-1960731-B | Method for regulating inflammatory and metastatic processes | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2011-12-07 | — | — | CN | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| CN-100526312-C | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| EP-1497287-A4 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2007-07-11 | — | — | EP | disclosed |
| CN-1976706-A | FGFR3 inhibition and treatment of multiple myeloma | CHIRON CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| CN-1960731-A | Method for regulating inflammatory and metastatic processes | CHIRON CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| CN-1692112-A | Benzimidazole quinolinones and uses thereof | CHIRON CORP (US) | 2005-11-02 | — | — | CN | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| CN-1659165-A | Quinolinone derivatives | CHIRON CORP (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1497287-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087095-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| CN-1226283-A | Recombinant enzyme with dextranase activity | NOVO NORDISK AS (DK) | 1999-08-18 | — | — | CN | disclosed |
| EP-0055428-B1 | BIS-(3-SULFOPROPYL)ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ALKYLATING AGENTS FOR ORGANIC BASES | Agfa-Gevaert AG (DE) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | ALDH1A1 1479/4885HTR2C 1306/4885HTR2B 1894/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | ALDH1A1 1479/4885HTR2C 1306/4885HTR2B 1894/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | ALDH1A1 1023/4885HTR2C 1559/4885HTR2B 1688/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | ALDH1A1 1479/4885HTR2C 1306/4885HTR2B 1894/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | ALDH1A1 1479/4885HTR2C 1306/4885HTR2B 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.